Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CARE-ATTR trial: Real-world effect of acoramidis on cardiac biomarkers in ATTR-CM
jRCT2071250063Recruiting
- Sponsor
- Alexion Pharmaceuticals
- Start
- Oct 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label trial of acoramidis in amyloidotic transthyretin cardiomyopathy (ATTR-CM) (2 arms), sponsored by Alexion Pharmaceuticals. Primary endpoint: Disease progression at 12 months. Started Oct 2025; status: recruiting.
02
Drugs
acoramidis
03
Conditions
amyloidotic transthyretin cardiomyopathy (ATTR-CM)
Beyond the preview
Go deeper on jRCT2071250063.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2071250063.